Appropriations Committees Release Three-Bill FY26 Funding Package: Labor, HHS, Education; Defense; Transportation, Housing and Urban Development

Congressional appropriations committees released a bipartisan, bicameral FY26 three‑bill funding package totaling roughly $1.2 trillion covering Labor/HHS/Education, Defense, and Transportation/HUD to fully fund the government before the Jan. 30 deadline. The package raises funding for the National Institutes of Health, increases transportation infrastructure spending, expands affordable housing and Homeless Assistance Grants (citing prevention of more than four million households becoming homeless), and includes a military pay raise, while House Republicans plan a separate Homeland Security vote.

Analysis

Market structure: The FY26 three‑bill package is a clear cyclical stimulus for defense, infrastructure and healthcare services — direct winners are large defense primes (LMT, NOC, RTX) and materials/aggregate producers (NUE, VMC) plus CROs/clinical suppliers (CRL, IQV). Housing allocations favor multifamily/affordable housing contractors and specialty REITs (AVB, MAA) rather than mass-market homebuilders; expect 3–12 month demand pull for steel/aggregate and a 5–15% pricing tailwind for materials over that window if projects proceed on schedule.

Risk assessment: Near-term removal of shutdown risk is positive for risk assets (days–weeks) but second‑order risks include state/local deployment capacity and supply‑chain/labor constraints that could push cost inflation and compress contractor margins in 3–9 months. Tail risks: partisan rerouting, sequestration, or DoD reprioritization could cut FY26 award flow (low probability, high impact). Key catalysts are DoD FY26 contract solicitations and NIH FOAs to be released in the next 60–180 days.

Trade implications: Tactical longs: defense primes and mid‑tier subs, steel/materials and CROs; preferred instrument construction is 6–12 month call spreads to capture award momentum while limiting theta. Relative plays: long industrials/construction exposure vs short long‑duration rates (expect fiscal spend to be modestly reflationary); monitor 10y Treasury — unwind if yields fall >20bp from entry.

Contrarian angles: The market will initially bid large primes; the alpha is likely in mid‑cap subs/engineering firms and specialty contractors that take market share from larger integrators (look for 10–30% upside potential). Beware consensus over‑pricing of long‑dated defense cashflows and underpricing of deployment risk at municipal/local level; if pipeline rollout lags >120 days, rotate out of materials into health‑services names benefiting from NIH cash flow timing.

Key Decisions for Investors

• Establish a 2.0% long position in Lockheed Martin (LMT) with target +12–15% over 6–12 months; prefer buying a 6–9 month call spread (buy 5–10% OTM, sell 20% OTM) to limit downside, stop-loss at -8% cash-equivalent move.
• Allocate 2.0% split equally to Charles River Labs (CRL) and IQVIA (IQV) (1.0% each) to capture NIH/biomedical services tailwinds; target +15–25% in 6–12 months, take profits on first +10% move and reassess after NIH FOA release (~60–180 days).
• Take a 1.5% long position in Nucor (NUE) to play steel demand from infrastructure (3–9 month horizon), target +10–15%; use a -10% stop and add if 10y Treasury yield rises >30bp (signaling reflation momentum).
• Implement a relative-value rotation: long XLI (Industrial ETF) 3.0% vs short TLT 2.0% (net equity tilt) for 3–6 months to play risk‑on/reflation; unwind if 10y yield drops >20bp or equity market volatility (VIX) >20 persists for 2 consecutive weeks.